Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous non-small cell lung cancer, hepatocellular carcinoma, renal cell carcinoma, and rare solid tumors, such as soft tissue sarcomas and thymic cancer. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. Show more

3963 Maple Avenue, Dallas, TX, 75219, United States

Biotechnology

Healthcare

Start AI Chat

Market Cap

59.95M

52 Wk Range

$5.67 - $42.79

Previous Close

$8.84

Open

$8.92

Volume

22,852

Day Range

$8.85 - $9.17

Enterprise Value

111.5M

Cash

79.67M

Avg Qtr Burn

-10.56M

Insider Ownership

6.29%

Institutional Own.

65.83%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ITIL-306 Details Cancer, Non-small cell lung carcinoma, Ovarian cancer, Renal cell carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AXN-2510/IMM2510 + chemotherapy Details Non-small cell lung carcinoma (NSCLC)	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AXN-2510 (formerly SYN-2510) /IMM2510 Details Relapsed/Refractory Solid Tumors	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ITIL-168 Details Cancer, Melanoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.